Statement On Lower Insulin Costs From BBT Executive Director Danielle Melfi
FOR IMMEDIATE RELEASE: March 1, 2023
PRESS CONTACT: [email protected]
STATEMENT ON LOWER INSULIN COSTS FROM BBT EXECUTIVE DIRECTOR DANIELLE MELFI
WASHINGTON, D.C. — Building Back Together Executive Director Danielle Melfi released the following statement after Eli Lilly announced they will cap the cost of insulin at $35 a month and lower the cost of other prescription drugs:
“This announcement is game changing for millions, and will particularly help low-income people and those without insurance. No one should have to choose between medication they need to survive and buying groceries or paying their bills. Lower costs for prescription drugs, including insulin, means more breathing room in household budgets — and that’s what President Biden’s cost-cutting agenda is all about.
“Today shows just how powerful it is to have an administration fighting on behalf of working people. President Biden called on Congress to pass his legislation to lower the cost of health care and prescription drugs – including capping the cost of insulin for Medicare recipients – and got it done. He called on Eli Lilly and other companies to stop price gouging and lower costs – and got it done. We celebrate this victory and thank the countless advocates who have worked for decades to get to this moment. Now it’s time for all Big Pharma companies to follow suit.”